

## **EZ-SARS-CoV-2 Real-Time RT-PCR Instructions for Use**

For the qualitative detection of SARS-CoV-2 viral RNA  
extracted from mid-turbinate nasal swab specimens

Catalog Number TC-5048-192

For *In Vitro* Diagnostic Use  
Rx Only  
For Use Under Emergency Use Authorization Only



**Table of Contents**

Intended Use .....	3
Summary and Explanation.....	3
Principles of the Procedure .....	3
Workflow Summary.....	4
Product Description .....	4
Storage and Stability .....	5
Warnings and Precautions.....	5
Specimen Collection and Storage .....	6
Test Controls.....	6
Nucleic Acid Extraction.....	7
Real-Time RT-PCR Test Procedure .....	7
Cycling Conditions and Instrument Settings.....	8
Analysis Settings.....	9
Interpretation of Test Results.....	9
Limitations .....	10
Conditions of Authorization for the Laboratory .....	11
Performance Characteristics .....	12
Appendix A: Procedure to Qualify RUO Instruments .....	20
Appendix B: Label for RUO Instruments .....	21
Symbols.....	22
Revision History .....	22
How to Obtain More Information .....	22

## **Intended Use**

The EZ-SARS-CoV-2 Real-Time RT-PCR is a real-time RT-PCR *in vitro* diagnostic test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in mid-turbinate nasal swab specimens from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in mid-turbinate nasal swab specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The EZ-SARS-CoV-2 Real-Time RT-PCR is intended for use by qualified clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and *in vitro* diagnostic procedures. The EZ-SARS-CoV-2 Real-Time RT-PCR is only for use under the Food and Drug Administration's Emergency Use Authorization.

## **Summary and Explanation**

An outbreak of pneumonia of unknown etiology in Wuhan City, Hubei Province, China was initially reported to WHO on December 31, 2019. Chinese authorities identified a novel coronavirus (2019-nCoV, also referred to as SARS-CoV-2), which has resulted in millions of confirmed human infections globally. Cases of asymptomatic infection, mild illness, severe illness, and deaths have been reported.

The Tetracore, Inc. EZ-SARS-CoV-2 Real-Time RT-PCR is a molecular *in vitro* test that aids in the detection and diagnosis of SARS-CoV-2 and is based on widely used nucleic acid amplification technology. The product contains oligonucleotide primers and dual-labeled hydrolysis probes (TaqMan®) and control material used in RT-PCR for the *in vitro* qualitative detection of SARS-CoV-2 RNA in mid-turbinate nasal swab specimens.

## **Principles of the Procedure**

The oligonucleotide primers and probes for detection of SARS-CoV-2 were selected from regions of the virus nucleocapsid protein (N) gene. The test is designed for specific detection of SARS-CoV-2 viral RNA. An additional primer/probe set to detect the endogenous human RNase P gene in clinical specimens is also included in the test, and a separate primer/probe set is included to detect a full process Inhibition Control (IC) added during sample extraction. Nucleic acids are isolated and purified from mid-turbinate nasal swab specimens using the QIAamp® Viral RNA Mini Kit following the manufacturer's recommended procedure. Using either the Applied Biosystems™ (ABI) 7500 Fast Real-Time PCR System or the Tetracore, Inc. T-COR 8™ Real-Time PCR Thermocycler, the purified nucleic acid is reverse transcribed into cDNA which is then subsequently amplified. In the process, the probe anneals to a specific target sequence located between the forward and reverse primers. During the extension phase of the PCR cycle, the 5' nuclease activity of Taq polymerase degrades the probe, causing the reporter dye to separate from the quencher dye, generating a fluorescent signal. With each cycle, additional reporter dye molecules are cleaved from their respective probes, increasing the fluorescence intensity. Fluorescence intensity is monitored at each PCR cycle by either the ABI 7500 Fast or the T-COR 8™.

**Workflow Summary**



**Product Description**

**EZ-SARS-CoV-2 Real-Time RT-PCR**

**Catalog Number: TC-5048-192**

**Materials Provided:**

Component	Contents
Mastermix	EZ-SARS-CoV-2 Real-Time RT-PCR Mastermix; 4 vials/kit (48 reactions per vial)
Enzyme	Enzyme Blend; 2 vials/kit
Inhibition Control	Inhibition Control <i>In Vitro</i> Transcript (IVT); 2 vials/kit
Positive Control	SARS-CoV-2 Non-Pathogenic Recombinant RNA Virus; 1 vial/kit

**Materials and Equipment Required, but Not Provided:**

- QIAamp® Viral RNA Mini Kit (Qiagen Cat. No. 52906)
- Ethanol (96–100%)
- 1.5 mL microcentrifuge tubes (DNase/RNase free)
- Applied Biosystems™ 7500 Fast Real-Time PCR System with SDS Software v1.4 or v1.5, or Tetracore, Inc. T-COR 8™ Real-Time PCR Thermocycler
- MicroAmp™ Fast Optical 96-Well Reaction Plates (Applied Biosystems Cat. No. 4346907) and MicroAmp™ Optical Adhesive Film (Applied Biosystems Cat. No. 4311971 or equivalent) or T-COR 8™ reaction tubes (Tetracore, Inc. Cat. No. TC-3006-500)
- T-COR 8™ tube rack (Tetracore, Inc. Cat. No. TC-3014-002)
- Micropipettes and sterile pipette tips with aerosol barriers
- Molecular biology grade water or 1X Tris-EDTA (pH 7.4)
- Microcentrifuge and centrifuge with a rotor that accommodates standard microplates
- Vortex mixer
- Laboratory freezers (-20°C and -80°C)

## **Storage and Stability**

The EZ-SARS-CoV-2 Real-Time RT-PCR Mastermix and Enzyme should be stored at -20°C (-15°C to -25°C), and are stable until the expiration date stated on the label. Avoid repeated (>2x) thawing and freezing of the Mastermix, and return any residual Mastermix to the freezer immediately after use. Protect the fluorogenic probes in the Mastermix from light. The Inhibition Control (IC) and Positive Control should be stored at -80°C (-60°C to -90°C). To avoid repeated freeze-thaws and subsequent degradation of the IC and Positive Control:

- Once thawed, make small working aliquots ( $\geq 30 \mu\text{L}$  per tube). Use 0.5 mL sterile microcentrifuge tubes with O-rings to avoid evaporation. Store the aliquots at -80°C (-60°C to -90°C). Limit each aliquot to no more than two freeze-thaws.
- Or make one-time use aliquots ( $\geq 30 \mu\text{L}$  per tube). Store the aliquots at -80°C (-60°C to -90°C).
- For short-term storage, the IC and Positive Control can be stored between 2°C and 8°C for no more than 12 hours.

## **Warnings and Precautions**

- For *in vitro* diagnostic use only. Rx only. For use under Emergency Use Authorization only.
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories.
- This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
- The EZ-SARS-CoV-2 Real-Time RT-PCR is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and *in vitro* diagnostic procedures.
- Handle all specimens as if infectious using safe laboratory procedures. Refer to *Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)* (<https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html>).
- Specimen processing should be performed in accordance with national biological safety regulations.
- If infection with SARS-CoV-2 is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions.
- Perform all manipulations of live virus samples within a Class II (or higher) biological safety cabinet (BSC).
- Use personal protective equipment such as (but not limited to) gloves, eye protection, and lab coats when handling kit reagents while performing this assay and handling materials including samples, reagents, pipettes, and other equipment and reagents.
- Amplification technologies such as PCR are sensitive to accidental introduction of PCR product from previous amplification reactions. Incorrect results could occur if either the clinical specimen or the real-time reagents used in the amplification step become contaminated by accidental introduction of amplification product (amplicon). Workflow in the laboratory should proceed in a unidirectional manner.
- Maintain separate areas for assay setup and handling of nucleic acids.
- Always check the expiration date prior to use. Do not use expired reagent. Do not substitute or mix reagent from different kit lots or from other manufacturers.
- Change aerosol barrier pipette tips between all manual liquid transfers.

- During preparation of samples, compliance with good laboratory techniques is essential to minimize the risk of cross-contamination between samples, and the inadvertent introduction of nucleases into samples during and after the extraction procedure. Proper aseptic technique should always be used when working with nucleic acids.
- Maintain separate, dedicated equipment (e.g., pipettes, microcentrifuges) and supplies (e.g., microcentrifuge tubes, pipette tips) for assay setup and handling of extracted nucleic acids.
- Wear a clean lab coat and powder-free disposable gloves (not previously worn) when setting up assays.
- Change gloves between samples and whenever contamination is suspected.
- Keep reagent and reaction tubes capped or covered as much as possible.
- During use, EZ-SARS-CoV-2 Real-Time RT-PCR Mastermix and Enzyme should be maintained on a cold block at all times during preparation and use.
- Work surfaces, pipettes, and centrifuges should be cleaned and decontaminated with cleaning products such as 10% bleach, DNAZap™ or RNase AWAY™ to minimize risk of nucleic acid contamination. Residual bleach should be removed using 70% ethanol.
- RNA should be maintained on cold block or on ice during preparation and use to ensure stability.
- Dispose of unused kit reagents and human specimens according to local, state, and federal regulations.

## **Specimen Collection and Storage**

Mid-turbinate nasal swab specimens should be collected, transported, stored, and processed according to CLSI MM13-A. Specimens should be stored at 2°C to 8°C until tested. If specimens cannot be tested within 72 hours of collection, they should be frozen at -70°C or colder until tested. Only swabs with a synthetic tip, such as nylon or Dacron®, and an aluminum or plastic shaft should be used to collect specimens. Calcium alginate swabs are unacceptable and cotton swabs with wooden shafts are not recommended. Place swabs immediately into sterile tubes containing sterile saline.

**Note:** Sample collection devices are not provided with the kit.

## **Test Controls**

### **Inhibition Control:**

A full process Inhibition Control is provided with the kit, and is added to the lysis buffer during the extraction process. A positive signal for the Inhibition Control indicates that all processing steps were successful.

### **Endogenous Control:**

The human RNase P gene primer and probe set included in the EZ-SARS-CoV-2 Real-Time RT-PCR serves as an endogenous internal control. It is used to monitor the adequacy of sample quantity and quality, nucleic acid extraction, and for detection of inhibitors in the extracted sample. The RNase P gene should be detected in every human sample tested, and its detection ensures that human nucleic acid was present in the sample.

### **Positive Control:**

A Positive Control is provided with the kit and must be included with each test run (tested on every RT-PCR plate on the ABI 7500 Fast or tested with each prepared mastermix on the T-COR 8™). The Positive Control is a non-pathogenic recombinant RNA virus that carries the entire sequence of SARS-CoV-2. The Positive Control is provided at a high concentration, and must be diluted before use with molecular biology grade water or 1X Tris-EDTA (pH 7.4) (not provided). See Step 3c of the Real-Time RT-PCR Test Procedure for Positive Control dilution instructions.

### **Negative Control:**

A Negative Control must be taken through all steps of the analysis process, including extraction. Molecular biology grade water or 1X Tris-EDTA (pH 7.4) (not provided) is recommended for use as a Negative Control. A Negative Control must be included with each extraction run. When testing samples on the ABI 7500 Fast, the

Negative Control from each extraction run must be tested on every RT-PCR plate. For example, if samples from four extraction runs are being combined on one 96-well RT-PCR plate, then the four associated Negative Controls must be run on that RT-PCR plate. When testing samples on the T-COR 8™, the associated Negative Control from the extraction run(s) must be included for each prepared mastermix (see Step 1 of the Real-Time RT-PCR Test Procedure). For example, if an extraction run consisting of 23 samples and one Negative Control is tested with two prepared mastermixes, that Negative Control must be tested with both prepared mastermixes.

**Nucleic Acid Extraction**

RNA should be extracted from mid-turbinate nasal swab specimens using the QIAamp® Viral RNA Mini Kit (Qiagen Cat. No. 52906, not provided) following the manufacturer’s recommended procedure. The use of other extraction protocols or commercial products should be validated by the user. The IC provided with the kit is a proprietary IVT that is utilized as a full process control added to the lysis buffer. Incorporate the IC into the RNA extraction process by adding 6.0 µL per sample of the IC to the extraction kit’s lysis buffer. The eluate at the end of the extraction process should contain the extracted IC.

**Real-Time RT-PCR Test Procedure**

**1. Preparing the Mastermix**

- Determine the total number of reactions needed (the number of extracted samples to be tested plus the required Positive and Negative Controls). Include additional reactions to account for loss during pipetting.
- Each vial of EZ-SARS-CoV-2 Real-Time RT-PCR Mastermix is guaranteed to contain enough reagents for 48 reactions.
  - a. Use the following table to calculate the volume of Mastermix and Enzyme needed per reaction.

**1 Reaction**

EZ-SARS-CoV-2 Mastermix	17.25 µL
Enzyme	0.75 µL
Total Mastermix Volume	18.00 µL

- b. Remove Mastermix vial(s) from the freezer. Thaw at room temperature. Once thawed, the Mastermix should be kept cold at all times. Gently vortex and briefly centrifuge the vial(s) before use.
- c. Remove Enzyme vial(s) from the freezer and briefly centrifuge (do not vortex). Return Enzyme vial(s) to the freezer immediately after use.

**Important:** Once the Enzyme is added to the Mastermix, the prepared Mastermix should be kept on ice and used within 2 hours.

**2. Aliquot 18.0 µL of the prepared Mastermix into each T-COR 8™ tube or well of a 96-well plate.**

**3. Prepare the Negative Control, Positive Control, and extracted sample reactions.**

**Note:** Always prepare the Negative Control first before handling either an extracted sample or the Positive Control.

**Note:** After the addition of extracted sample or control to the prepared Mastermix, pipette-mix to ensure a homogeneous solution.

- a. Negative Control(s):  
Add 7.0 µL of the extracted Negative Control to a T-COR 8™ tube or well of a 96-well plate that contains 18.0 µL of the prepared Mastermix.

- b. Extracted Sample(s):  
Add 7.0  $\mu\text{L}$  of the extracted sample to a T-COR 8™ tube or well of a 96-well plate that contains 18.0  $\mu\text{L}$  of the prepared Mastermix.
- c. Positive Control:  
Before use, dilute the provided Positive Control by combining 7.0  $\mu\text{L}$  of the Positive Control with 93.0  $\mu\text{L}$  of molecular biology grade water or 1X Tris-EDTA (pH 7.4) (not provided).  
Add 7.0  $\mu\text{L}$  of the diluted Positive Control to a T-COR 8™ tube or well of a 96-well plate that contains 18.0  $\mu\text{L}$  of the prepared Mastermix.

**Note:** The diluted Positive Control should be used directly after preparation, and should not be stored for subsequent reuse.

**4. Cap the T-COR 8™ tubes, or seal the 96-well plate with MicroAmp™ Optical Adhesive Film and briefly centrifuge.**

**Note:** To cap the T-COR 8™ tubes properly: With the T-COR 8™ tube in the T-COR 8™ tube rack, align the cap to the opening of the T-COR 8™ tube and apply firm downward pressure on the cap until no gaps are seen between the cap and the tube.

**Note:** Ensure that all of the liquid is at the bottom of each tube or well, and that no bubbles are present. Centrifuge the plate again or gently tap the T-COR 8™ tubes if needed.

**5. Load the T-COR 8™ tubes into the T-COR 8™ Real-Time PCR Thermocycler or the 96-well plate into the Applied Biosystems™ 7500 Fast Real-Time PCR System, and follow the thermal cycling protocol below.**

### **Cycling Conditions and Instrument Settings**

The EZ-SARS-CoV-2 Real-Time RT-PCR assay utilizes different reporter dyes to distinguish between targets (see table below).

Target	Reporter Dye Channel
SARS-CoV-2	FAM
IC	TAMRA/DFO
RNase P	Cy5

**ABI 7500 Fast Thermal Cycling Protocol and Settings:**

Stage 1: 48°C for 15 minutes

Stage 2: 95°C for 2 minutes

Stage 3: 45 cycles (2-step PCR):

Step 1: 95°C for 10 seconds

Step 2: 60°C for 40 seconds (data collection step)

- Use 7500 System SDS Software Version 1.4 or 1.5
- Select Run Mode: Standard 7500
- Do **NOT** select ROX as a Passive Reference dye. The Mastermix does **NOT** contain ROX
- Assay: Standard Curve (Absolute Quantitation)
- SARS-CoV-2: Select detector for FAM as reporter dye and None as quencher
- IC: Select detector for TAMRA as reporter dye and None as quencher
- RNase P: Select detector for Cy5 as reporter dye and None as quencher
- Sample Volume: 25  $\mu\text{L}$



**T-COR 8™ Thermal Cycling Protocol and Settings:**

Repeat x1: Go to temperature 48°C, Hold for 300 seconds  
Go to temperature 95°C, Hold for 30 seconds

Repeat x5: Go to temperature 95°C, Hold for 10 seconds  
Go to temperature 60°C, Hold for 40 seconds

**Optics on**

Repeat x40: Go to temperature 95°C, Hold for 5 seconds  
Go to temperature 60°C, Hold for 20 seconds

**Optics on**

- Settings: FAM: 160 DFO: 160 TxR: 160 Cy5: 160  
Active cooling
- Analysis: Per-Well SmartCT™

**Analysis Settings****ABI 7500 Fast**

1. When the run is complete, select the Amplification Plot tab to view the amplification curves. From the Tools menu, click on Graph Settings. Change Post Run Settings to Linear Y-axis and select Auto Scale.
2. Adjust the baseline manually as necessary for each dye channel.
3. For the FAM dye channel, set the Threshold at 3% of the final normalized fluorescence of the Positive Control amplification curve. For the TAMRA dye channel, set the Threshold at 3% of the final normalized fluorescence of the Negative Control amplification curve.

**Example:** In the FAM channel, the final Positive Control fluorescence at cycle 45 is approximately 2.0e+006 and 3% of 2.0e+006 is 6.0e+004. Therefore, set the threshold for the FAM channel at 6.0e+004.

4. View each well individually to verify true amplification.

**T-COR 8™**

1. The user can monitor temperature and fluorescence curves in real time, as well as select graphs for different dye channels in the [View] menu.
2. When the run is complete, the T-COR 8™ software will automatically display a table or graph of the final results.
3. The T-COR 8™ Smart CT™ algorithm calculates the Ct value based on the shape of the curve instead of a threshold value. Select the [View] menu and then select the [SmartCT™ Values] option to view the Smart CT™ Values table.
4. Select graphs for each dye channel in the [View] menu to verify true amplification for each well.

**Interpretation of Test Results**

All test controls should be examined prior to interpretation of patient results. If the controls are not valid, the patient results cannot be interpreted. Amplification plots for all test controls and patient specimens should be reviewed to discern true amplification from baseline drift.

**EZ-SARS-CoV-2 Real-Time RT-PCR Test Controls:**

The expected results for the EZ-SARS-CoV-2 Real-Time RT-PCR test controls are detailed in the tables below. Failure of either the Positive Control or the Negative Control invalidates the RT-PCR run and results should not be reported. If an invalid control result is produced, the RT-PCR run should be repeated. If the invalid results repeat, re-extract the patient specimens with a Negative Control and test again.

**Expected Performance of EZ-SARS-CoV-2 Real-Time RT-PCR Test Controls on the ABI 7500 Fast**

Control Name	Expected Ct Values		
	SARS-CoV-2	IC	RNase P
Positive Control	< 40	Not Evaluated	-*
Negative Control	-*	≤ 30	-*

\*-, Ct value ≥ 40

**Expected Performance of EZ-SARS-CoV-2 Real-Time RT-PCR Test Controls on the T-COR 8™**

Control Name	Expected Ct Values		
	SARS-CoV-2	IC	RNase P
Positive Control	< 40	Not Evaluated	-*
Negative Control	-*	≤ 34	-*

\*-, Ct value ≥ 40

**Examination and Interpretation of Patient Specimen Results:**

Assessment of clinical specimen test results should be performed after the Positive and Negative Controls have been examined and determined to be valid and acceptable. If the controls are not valid, the patient results cannot be interpreted. Interpretation of the results from patient specimens is detailed in the table below. Any patient specimen that produces an invalid result must be retested by re-extracting the original sample and repeating the RT-PCR. If the retest result is also invalid, a new specimen should be collected from the patient and tested following this procedure.

**Interpretation of Results from Patient Specimens**

SARS-CoV-2	Results*		Interpretation
	IC	RNase P	
+	+	+	SARS-CoV-2 Detected
+	+	-	SARS-CoV-2 Detected
+	-	+	SARS-CoV-2 Detected
+	-	-	SARS-CoV-2 Detected
-	+	+	SARS-CoV-2 Not Detected
-	+	-	Invalid
-	-	+	Invalid
-	-	-	Invalid

\*+, Ct value < 40; -, Ct value ≥ 40

**Limitations**

- The EZ-SARS-CoV-2 Real-Time RT-PCR is used for qualitative detection of SARS-CoV-2 RNA from human mid-turbinate nasal swab specimens. The Ct result cannot directly reflect the viral load in the original specimen.
- The EZ- SARS-CoV-2 Real-Time RT-PCR performance was assessed with mid-turbinate nasal swabs collected in saline, only.
- Negative results in the EZ-SARS-CoV-2 Real-Time RT-PCR do not preclude SARS-CoV-2 infection, and should not be used as the sole basis for treatment or other patient management decisions.
- A false negative result may occur if a specimen is improperly collected, transported or handled. False negative results may also occur if amplification inhibitors are present in the specimen or if inadequate numbers of organisms are present in the specimen.
- If mutations occur in the primer and probe binding regions targeted by the EZ-SARS-CoV-2 Real-Time RT-PCR, SARS-CoV-2 RNA may become undetectable, leading to false negative results.
- The EZ-SARS-CoV-2 Real-Time RT-PCR has not been evaluated for asymptomatic testing or specimen pooling.

- The performance of this test was established based on the evaluation of a limited number of clinical specimens. Clinical performance has not been established with all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.
- Inappropriate specimen preparation and operation may lead to inaccurate results. A false positive result may occur if there is cross-contamination by SARS-CoV-2 virus, nucleic acid or amplified product that is introduced in a patient specimen.
- Detection of viral RNA may not indicate the presence of infectious virus or that SARS-CoV-2 is the causative agent for clinical symptoms.
- This test cannot rule out diseases caused by other bacterial or viral pathogens.
- The impact of vaccines, antiviral therapeutics, antibiotics, chemotherapeutics or immunosuppressant drugs on test performance have not been evaluated.
- Extraction and amplification of nucleic acid from clinical specimens must be performed according to the specified methods listed in these instructions. Other extraction approaches and processing systems have not been evaluated.
- Amplification and detection of SARS-CoV-2 with this test has only been validated with the instruments specified in these instructions. Use of other instrument systems may cause inaccurate results.

### **Conditions of Authorization for the Laboratory**

The EZ-SARS-CoV-2 Real-Time RT-PCR Letter of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients, and authorized labeling are available on the FDA website:

<https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>

However, to assist clinical laboratories using the EZ-SARS-CoV-2 Real-Time RT-PCR (“your product” in the conditions below), the relevant Conditions of Authorization are listed below:

- A. Authorized laboratories<sup>1</sup> using your product must include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- B. Authorized laboratories using your product must use your product as outlined in the authorized labeling. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.
- C. Authorized laboratories that receive your product must notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- D. Authorized laboratories using your product must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- E. Authorized laboratories must collect information on the performance of your product and must report any significant deviations from the established performance characteristics of your product of which they become aware to DMD/OHT7/OPEQ/CDRH (via email: [CDRH-EUA-Reporting@fda.hhs.gov](mailto:CDRH-EUA-Reporting@fda.hhs.gov)) and Tetracore, Inc. (via email: [sales@tetracore.com](mailto:sales@tetracore.com) or via phone: 240.268.5400).
- F. All laboratory personnel using your product must be appropriately trained in real-time RT-PCR techniques, and use appropriate laboratory and personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.
- G. Tetracore, Inc, its authorized distributor(s) and authorized laboratories using the EZ-SARS-CoV-2 Real-Time RT-PCR must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records must be made available to FDA for inspection upon request.

---

<sup>1</sup> The letter of authorization refers to, “Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests” as “authorized laboratories.”

## **Performance Characteristics**

### **Limit of Detection (LoD) - Analytical Sensitivity**

The LoD study established the lowest detectable concentration of SARS-CoV-2 (genomic copy equivalents or GCE) at which 95% of all (true positive) replicates test positive with the EZ-SARS-CoV-2 Real-Time RT-PCR. Mid-turbinate nasal swab specimens collected in 1 mL sterile saline obtained from individuals who tested negative for SARS-CoV-2 were pooled and spiked with gamma-irradiated SARS-Related Coronavirus 2, Isolate USA-WA1/2020 (BEI Resources NR-52287). The pooled clinical matrix was screened negative using the EZ-SARS-CoV-2 Real-Time RT-PCR prior to spiking. To estimate the LoD, serial dilutions of SARS-CoV-2 were made in the clinical matrix and tested in three replicates. Each viral dilution was added to three swabs (50 µL per swab head). The swabs were each then eluted in 1 mL sterile saline and processed through the EZ-SARS-CoV-2 Real-Time RT-PCR workflow, including nucleic acid extraction using the Qiagen QIAamp® Viral RNA Mini Kit following the manufacturer’s recommended procedure with the Inhibition Control added to the lysis buffer. Real-time PCR for the EZ-SARS-CoV-2 Real-Time RT-PCR was carried out on the Applied Biosystems 7500 Fast Real-Time PCR System and the T-COR 8™ Real-Time PCR Thermocycler. The lowest concentration at which all three replicates were positive was treated as the preliminary LoD for each real-time PCR instrument. The preliminary LoD was determined to be 3 GCE per reaction for both real-time PCR instruments (see Tables 1 and 2).

**Table 1.** Preliminary LoD study results on the ABI 7500 Fast.

Effective Concentration	Replicate	SARS-CoV-2 Ct Value	IC Ct Value	RNase P Ct Value	Detection Rate
300 GCE/reaction	1	28.6	26.8	29.2	100%
	2	28.7	26.6	29.2	
	3	28.4	26.9	29.1	
100 GCE/reaction	1	30.2	26.5	29.2	100%
	2	30.3	27.1	29.1	
	3	30.0	27.0	29.2	
30 GCE/reaction	1	32.0	27.2	29.1	100%
	2	31.9	27.0	29.1	
	3	31.8	27.1	29.5	
10 GCE/reaction	1	33.7	27.2	29.1	100%
	2	34.2	26.9	29.4	
	3	33.8	27.0	29.1	
3 GCE/reaction	1	34.9	26.6	29.2	100%
	2	35.5	27.0	29.3	
	3	36.2	26.8	29.3	
1 GCE/reaction	1	-	27.0	29.2	66.7%
	2	36.7	27.2	29.6	
	3	36.7	27.2	29.1	
0.3 GCE/reaction	1	-	26.7	29.5	0%
	2	-	26.8	29.3	
	3	-	26.9	29.3	

**Table 2.** Preliminary LoD study results on the T-COR 8™.

Effective Concentration	Replicate	SARS-CoV-2 Ct Value	IC Ct Value	RNase P Ct Value	Detection Rate
300 GCE/reaction	1	30.7	28.3	30.3	100%
	2	31.0	28.3	30.2	
	3	30.7	28.9	30.4	
100 GCE/reaction	1	32.9	28.7	30.5	100%
	2	32.3	28.8	30.5	
	3	32.1	28.7	30.4	
30 GCE/reaction	1	34.1	28.9	30.6	100%
	2	33.7	28.8	30.1	
	3	34.2	28.9	30.9	
10 GCE/reaction	1	35.2	28.6	30.2	100%
	2	35.7	28.8	30.6	
	3	35.8	28.8	30.3	
3 GCE/reaction	1	36.9	28.6	30.5	100%
	2	36.8	28.7	30.7	
	3	36.1	28.8	30.9	
1 GCE/reaction	1	-	28.8	30.8	66.7%
	2	37.5	29.0	30.7	
	3	38.0	29.0	30.8	
0.3 GCE/reaction	1	-	28.5	30.9	0%
	2	-	28.7	30.7	
	3	-	28.8	30.6	

The confirmatory LoD study was performed in the same manner as the preliminary LoD study described above. Twenty replicates were tested at the preliminary LoD of 3 GCE per reaction on the ABI 7500 Fast and T-COR 8™ real-time PCR instruments (see Tables 3 and 4). The LoD was determined to be 3 GCE per reaction for both real-time PCR instruments.

**Table 3.** Confirmatory LoD study results on the ABI 7500 Fast.

Effective Concentration	Replicate	SARS-CoV-2 Ct Value	IC Ct Value	RNase P Ct Value	Detection Rate
3 GCE/reaction	1	35.0	27.0	29.1	100%
	2	35.0	26.6	29.1	
	3	35.2	26.6	29.4	
	4	35.1	26.2	29.0	
	5	34.7	26.6	29.1	
	6	35.6	26.4	29.0	
	7	35.6	26.7	29.1	

	8	34.8	26.6	29.0	
	9	35.0	26.5	29.0	
	10	34.4	26.7	29.0	
	11	34.9	26.6	29.0	
	12	36.1	26.6	29.1	
	13	34.8	26.4	29.2	
	14	36.2	26.3	29.1	
	15	35.3	26.4	29.0	
	16	36.0	26.5	29.1	
	17	34.7	26.6	29.1	
	18	34.2	26.6	29.0	
	19	36.8	26.7	29.3	
	20	34.9	26.4	29.0	

**Table 4.** Confirmatory LoD study results on the T-COR 8™.

Effective Concentration	Replicate	SARS-CoV-2 Ct Value	IC Ct Value	RNase P Ct Value	Detection Rate
3 GCE/reaction	1	36.5	28.7	30.0	100%
	2	37.0	28.8	30.4	
	3	36.1	28.8	30.8	
	4	36.9	28.6	30.6	
	5	37.1	28.9	30.5	
	6	36.3	28.4	30.5	
	7	36.0	28.8	30.5	
	8	37.5	28.9	30.5	
	9	36.5	28.8	30.4	
	10	37.5	28.7	30.4	
	11	36.0	28.3	30.2	
	12	37.5	28.5	30.5	
	13	35.7	28.3	30.5	
	14	36.7	28.3	30.6	
	15	37.4	28.4	30.5	
	16	36.6	28.7	30.5	
	17	36.2	28.6	30.5	
	18	36.5	28.4	30.3	
	19	36.9	28.7	30.6	
	20	36.4	28.5	30.4	

**Inclusivity (*In Silico* Analysis)**

Updated *in silico* analyses are performed on a regular basis evaluating the mismatch frequency of the N gene primer and probe sequences using SARS-CoV-2 sequences in the GISAID database (<https://www.gisaid.org>). As of October 11, 2023, the assessment of homology between these SARS CoV-2 sequences shows that the risk of significant loss of signal amplification and/or false negative results is very low due to the absence of a significant numbers of mismatches. Because the EZ-SARS-CoV-2 Real-Time RT-PCR utilizes a single reporter dye (FAM) for detection of all N gene targets, mismatches would need to be present in all N gene assay regions to produce a false negative result. Furthermore, the EZ-SARS-CoV-2 Real-Time RT-PCR is expected to tolerate a single mismatch greater than 5 bases from the 3' end of a primer or a single mismatch in a probe.

**Cross-reactivity (Analytical Specificity)****In Silico Analysis**

BLASTn analysis queries of the EZ-SARS-CoV-2 Real-Time RT-PCR assays primers and probes were performed against public domain nucleotide sequences. The database search parameters were as follows: 1) The nucleotide collection consists of GenBank NT and RefSeq sequences, but excludes EST, STS, GSS, WGS, TSA, patent; 2) The database is non-redundant. Identical sequences have been merged into one entry, while preserving the accession, GI, title and taxonomy information for each entry; 3) Database(s) was updated on 08/15/2021; 4) The search parameters automatically adjust for short input sequences and the expected threshold is 1000; 5) The match and mismatch scores are 1 and -3, respectively. Additionally, Needleman–Wunsch alignments were performed against a defined set of data containing all the sequences in Table 5.

Each primer and probe was aligned to the sequences listed in Table 5. The alignment used the Needleman Wunsch global alignment implemented by seq-align as well as NCBI BLASTn tools. No gaps were allowed in the alignment and a match matrix was used. The matrix scored the alignment with a 1 for match and a 0 for anything else. The alignment score was the number of matches between the primer or probe and the pathogen. The frequency of the alignment is the number of matches divided by the length of the primer or probe.

The probe sequence of one of the EZ-SARS-CoV-2 Real-Time RT-PCR N gene assays matches to the genome of SARS coronavirus Urbani with an identity of 96%. However, the forward and reverse primers show reduced homology (forward primer 70% and reverse primer 92% with two key mismatches). These primers and probe have no significant homologies with the human genome, other coronaviruses or human microflora that would predict potential for interference or false positive real-time RT-PCR results. The forward primer sequence of another EZ-SARS-CoV-2 Real-Time RT-PCR N gene assay showed 100% sequence identity to SARS coronavirus Urbani. The reverse primer and probe sequences showed less significant homology with SARS coronavirus Urbani, as well as the human genome, other coronaviruses or human microflora (the BLASTn expectation value was greater than 1.0). Wet testing was performed with SARS coronavirus Urbani as part of the Cross-reactivity wet testing study and was shown to not cross-react with the EZ-SARS-CoV-2 Real-Time RT-PCR assay (see Table 6).

In summary, the EZ-SARS-CoV-2 Real-Time RT-PCR N gene assays, designed for the specific detection of SARS-CoV-2, showed no significant combined homologies with the human genome, other coronaviruses, or human microflora that would predict potential false positive real-time RT-PCR results.

**Table 5.** EZ-SARS-CoV-2 Real-Time RT-PCR cross-reactivity (*in silico* analysis).

Pathogen	Strain	GenBank Accession No.
Adenovirus	Human adenovirus type 1, complete genome	AC_000017.1
<i>Bordetella pertussis</i>	Bordetella pertussis strain B3921, complete genome	CP011448.1
<i>Candida albicans</i>	Candida albicans strain L757 mitochondrion, complete genome	NC_018046.1
<i>Chlamydia pneumoniae</i>	Chlamydia pneumoniae genome assembly PB2, chromosome: 1	NZ_LN847241.1
Enterovirus	Human enterovirus 68 isolate EV68_NL_201013421 VP1 protein gene, partial cds	JF896312.1
<i>Haemophilus influenzae</i>	Haemophilus influenzae PittGG, complete genome	CP000672.1
Human coronavirus 229E	Human coronavirus 229E strain 229E/human/USA/932-72/1993, complete genome	KF514432.1
Human coronavirus 229E	Human coronavirus 229E strain 229E/human/USA/933-40/1993, complete genome	KF514433.1
Human coronavirus HKU1	Human coronavirus HKU1 isolate SI17244, complete genome	MH940245.1
Human coronavirus HKU1	Human coronavirus HKU1 strain HKU1/human/USA/HKU1-18/2010, complete genome	KF430201.1
Human coronavirus NL63	Human coronavirus NL63 strain NL63/human/USA/891-4/1989, complete genome	KF530114.1
Human coronavirus NL63	Human coronavirus NL63 strain NL63/human/USA/905-25/1990, complete genome	KF530113.1
Human coronavirus OC43	Human coronavirus OC43 isolate LRTI_238, complete genome	KX344031.1
Human coronavirus OC43	Human coronavirus OC43 strain OC43/human/USA/971-5/1997, complete genome	KF530099.1
Human Metapneumovirus (hMPV)	Human metapneumovirus strain HMPV/Homo sapiens/PER/FPP00726/2011/A, complete genome	KJ627437.1
Influenza A	Influenza A virus (A/New York/PV305/2017(H1N1)) segment 2 polymerase PB1 (PB1) gene, complete cds and functional PB1-F2 protein (PB1-F2) gene, complete sequence	MH798556.1
Influenza B	Influenza B virus (B/Nicaragua/8689_13/2017) segment 2 polymerase PB2 (PB2) gene, complete cds	MK969560.1
<i>Legionella pneumophila</i>	Legionella pneumophila strain Philadelphia_1_CDC, complete genome	CP015928.1
MERS-Coronavirus	Middle East respiratory syndrome-related coronavirus strain HcoV-EMC, complete genome	MH013216.1
<i>Mycobacterium tuberculosis</i>	Mycobacterium tuberculosis DNA, complete genome, strain: HN-506	AP018036.1
<i>Mycoplasma pneumoniae</i>	Mycoplasma pneumoniae strain 14-637 chromosome, complete genome	CP039772.1
Parainfluenza 1	Human parainfluenza virus 1 isolate NM001, complete genome	KX639498.1
Parainfluenza 2	Human parainfluenza virus 2 isolate VIROAF10, complete genome	KM190939.1
Parainfluenza 3	Human parainfluenza virus 3 strain HPIV3/AUS/3/2007, complete genome	KF530243.1
Parainfluenza 4	Human parainfluenza virus 4a isolate HPIV4_DK (459), complete genome	KF483663.1



<i>Pneumocystis jirovecii</i>	Pneumocystis jirovecii isolate SW7_full mitochondrion, complete genome	MH010446.1
<i>Pseudomonas aeruginosa</i>	Pseudomonas aeruginosa UCBPP-PA14, complete genome	CP000438.1
Respiratory syncytial virus	Respiratory syncytial virus strain B/WI/629-Q0190/10, complete genome	JN032120.1
Rhinovirus	Human rhinovirus 14, complete genome	NC_001490.1
SARS-coronavirus	SARS coronavirus Urbani, complete genome	AY278741.1
SARS-CoV-2	Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome	NC_045512.2
<i>Staphylococcus epidermidis</i>	Staphylococcus epidermidis strain SP3 16S ribosomal RNA gene, partial sequence	KY750253.1
<i>Streptococcus pneumoniae</i>	Streptococcus pneumoniae strain D39V chromosome, complete genome	CP027540.1
<i>Streptococcus pyogenes</i>	Streptococcus pyogenes MGAS8232, complete genome	AE009949.1
<i>Streptococcus salivarius</i>	Streptococcus salivarius strain LAB813 chromosome, complete genome	CP040804.1

### **Wet Testing**

To confirm the cross-reactivity of the EZ-SARS-CoV-2 Real-Time RT-PCR in the wet test condition, 40 non-target organisms were prepared by extracting each standard organism (concentration of  $> 10^6$  CFU/mL for bacteria/fungi or  $> 10^4$  TCID<sub>50</sub>/mL for viruses, when available from the vendor) using the Qiagen QIAamp® Viral RNA Mini Kit. Real-time PCR for the EZ-SARS-CoV-2 Real-Time RT-PCR was carried out on the Applied Biosystems 7500 Fast Real-Time PCR System and the T-COR 8™ Real-Time PCR Thermocycler. Testing was performed in triplicate on the ABI 7500 Fast, and a minimum of one replicate was tested on the T-COR 8™. As a result, all 40 non-target samples were not detected (see Table 6).

**Table 6.** EZ-SARS-CoV-2 Real-Time RT-PCR cross-reactivity (wet testing).

Organism	Source	Isolate No.	Replicates Detected/Total	
			7500 Fast	T-COR 8™
Human coronavirus 229E	Zeptomatrix	0810229CF	0/3	0/1
Human coronavirus OC43	Zeptomatrix	0810024CF	0/3	0/1
Human coronavirus NL63	BEI Resources	NR-470	0/3	0/1
SARS coronavirus Urbani	BEI Resources	NR-9547	0/3	0/1
MERS coronavirus	BEI Resources	NR-45843*	0/3	0/1
Adenovirus Type 7A	Zeptomatrix	0810021CF	0/3	0/1
Adenovirus Type 1	Zeptomatrix	0810050CF	0/3	0/1
Adenovirus Type 4	Zeptomatrix	0810070CF	0/3	0/1
Human metapneumovirus (hMPV) 16 Type A1	Zeptomatrix	0810161CF	0/3	0/1
Parainfluenza virus 1	BEI Resources	NR-48680	0/3	0/1
Parainfluenza virus 2	BEI Resources	NR-3229	0/3	0/1
Parainfluenza virus 3	BEI Resources	NR-3233	0/3	0/1
Parainfluenza virus 4A	BEI Resources	NR-3237	0/3	0/1
Parainfluenza virus 4B	BEI Resources	NR-3238	0/3	0/1
Influenza A H1N1	BEI Resources	NR-13663	0/3	0/1
Influenza A H3N2	BEI Resources	NR-41803	0/3	0/1

Influenza B	BEI Resources	NR-42006	0/3	0/1
Enterovirus Type 68	Zeptomatrix	0810237CF	0/3	0/1
Enterovirus 71	BEI Resources	NR-471	0/3	0/1
Enterovirus D68	BEI Resources	NR-49131	0/3	0/1
Respiratory syncytial virus A1998/3-2	BEI Resources	NR-28529	0/3	0/3
Respiratory syncytial virus B1	BEI Resources	NR-4052	0/3	0/3
Respiratory syncytial virus A1998/12-21	BEI Resources	NR-28528	0/3	0/3
Rhinovirus 20, 15-CV19	BEI Resources	NR-51439	0/3	0/1
Rhinovirus 60, 2268-CV37	BEI Resources	NR-51447	0/3	0/1
Rhinovirus 34, 137-3	BEI Resources	NR-51451	0/3	0/1
<i>Chlamydia pneumoniae</i>	ATCC	53592	0/3	0/1
<i>Haemophilus influenzae</i>	ATCC	33391	0/3	0/1
<i>Legionella pneumophila</i>	Zeptomatrix	0801645	0/3	0/1
<i>Mycobacterium tuberculosis</i>	Zeptomatrix	0801660	0/3	0/1
<i>Streptococcus pneumoniae</i>	ATCC	49619	0/3	0/1
<i>Streptococcus pyogenes</i>	ATCC	10782	0/3	0/1
<i>Bordetella pertussis</i>	BEI Resources	NR-42460	0/3	0/1
<i>Mycoplasma pneumoniae</i>	Zeptomatrix	0801579	0/3	0/1
<i>Pneumocystis jirovecii</i> (PJP)	ATCC	PRA-159	0/3	0/1
Pooled human nasal wash	In-House		0/3	0/1
<i>Candida albicans</i>	ATCC	18804	0/3	0/1
<i>Pseudomonas aeruginosa</i>	ATCC	27853	0/3	0/1
<i>Staphylococcus epidermidis</i>	ATCC	14990	0/3	0/1
<i>Streptococcus salivarius</i>	ATCC	13419	0/3	0/1

\*Isolate NR-45843 was received as nucleic acid extracted from a preparation of MERS-CoV, EMC/2012 (BEI Resources NR-44260) using the QIAamp® Viral RNA Mini Kit (Qiagen 52906), and was therefore not further extracted.

### Clinical Evaluation

Blinded panels totaling 86 clinical specimens were tested at CLIA high-complexity laboratories which characterized the samples for SARS-CoV-2 by the use of an FDA-Emergency Use Authorized high sensitivity RT-PCR comparator SARS-CoV-2 assay that includes solid phase nucleic acid extraction. The specimens were mid-turbinate nasal swabs in sterile saline collected from patients suspected of COVID-19 by their healthcare provider. Fifty-four of the clinical specimens had SARS-CoV-2 positive test results, and 32 had SARS-CoV-2 negative test results by the comparator assay. Among the 54 positive specimens, >50% were considered low positives by the comparator assay. The blinded specimen panel was processed through the EZ-SARS-CoV-2 Real-Time RT-PCR workflow and tested on the Applied Biosystems 7500 Fast Real-time PCR System and the T-COR 8™ Real-time PCR Thermocycler. Fifty-three of the 54 specimens found to be positive for SARS-CoV-2 by the comparator assay also gave positive results when tested with the EZ-SARS-CoV-2 Real-Time RT-PCR on both the ABI 7500 Fast and the T-COR 8™. All 32 specimens found to be negative for SARS-CoV-2 by the comparator assay also gave negative results when tested with the EZ-SARS-CoV-2 Real-Time RT-PCR on both the ABI 7500 Fast and the T-COR 8™. The clinical performance of the EZ-SARS-CoV-2 Real-Time RT-PCR when run on the ABI 7500 Fast and T-COR are shown in Table 7 and Table 8, respectively.

**Table 7.** Clinical performance of the EZ-SARS-CoV-2 Real-Time RT-PCR on the ABI 7500 Fast.

EZ-SARS-CoV-2 Real-Time RT-PCR	Comparator RT-PCR Assay		Total
	Positive	Negative	
<b>Positive</b>	53	0	53
<b>Negative</b>	1	32	33
<b>Total</b>	<b>54</b>	<b>32</b>	<b>86</b>
<b>Positive Percent Agreement (PPA)</b>			
		98.1% (53/54), 95% CI: (90.2%, 99.7%)	
<b>Negative Percent Agreement (NPA)</b>			
		100% (32/32), 95% CI: (89.3%, 100%)	

**Table 8.** Clinical performance of the EZ-SARS-CoV-2 Real-Time RT-PCR on the T-COR 8™.

EZ-SARS-CoV-2 Real-Time RT-PCR	Comparator RT-PCR Assay		Total
	Positive	Negative	
<b>Positive</b>	53	0	53
<b>Negative</b>	1	32	33
<b>Total</b>	<b>54</b>	<b>32</b>	<b>86</b>
<b>Positive Percent Agreement (PPA)</b>			
		98.1% (53/54), 95% CI: (90.2%, 99.7%)	
<b>Negative Percent Agreement (NPA)</b>			
		100% (32/32), 95% CI: (89.3%, 100%)	

## **Appendix A: Procedure to Qualify RUO Instruments**

Laboratories that use the ABI 7500 Fast Real-Time PCR System or the Tetracore, Inc. T-COR 8™ Real-Time PCR Thermocycler should use this procedure to qualify their RUO instrument(s) for testing using the EZ-SARS-CoV-2 Real-Time RT-PCR.

### **Materials Required\*:**

<b>Material</b>	<b>Description</b>
Mastermix	EZ-SARS-CoV-2 Real-Time RT-PCR Mastermix; included in the kit
Enzyme	Enzyme Blend; included in the kit
Positive Control	SARS-CoV-2 Non-Pathogenic Recombinant RNA Virus; included in the kit
Diluent	Molecular biology grade water or 1X Tris-EDTA (pH 7.4); not provided

\*See also “Product Description” on page 4.

### **Procedure:**

1. Prepare a Mastermix as described in Step 1 of the “Real-Time RT-PCR Test Procedure” for 9 reactions.
2. Aliquot 18.0 µL of the prepared Mastermix into 8 T-COR 8™ tubes or 8 wells of a 96-well plate.
3. Add 7.0 µL of the provided Positive Control to 4 T-COR 8™ tubes or 4 wells of a 96-well plate that contain 18.0 µL of the prepared Mastermix. Pipette-mix to ensure a homogeneous solution.
4. Dilute the provided Positive Control by combining 7.0 µL of the Positive Control with 93.0 µL of molecular biology grade water or 1X Tris-EDTA (pH 7.4) (not provided). Add 7.0 µL of the diluted Positive Control to 4 T-COR 8™ tubes or 4 wells of a 96-well plate that contain 18.0 µL of the prepared Mastermix. Pipette-mix to ensure a homogeneous solution.

**Note:** The diluted Positive Control should be used directly after preparation, and should not be stored for subsequent reuse.

5. Cap the T-COR 8™ tubes, or seal the 96-well plate with MicroAmp™ Optical Adhesive Film and briefly centrifuge.

**Note:** To cap the T-COR 8™ tubes properly: With the T-COR 8™ tube in the T-COR 8™ tube rack, align the cap to the opening of the T-COR 8™ tube and apply firm downward pressure on the cap until no gaps are seen between the cap and the tube.

**Note:** Ensure that all of the liquid is at the bottom of each tube or well, and that no bubbles are present. Centrifuge the plate again or gently tap the T-COR 8™ tubes if needed.

6. Load the T-COR 8™ tubes into the T-COR 8™ Real-Time PCR Thermocycler or the 96-well plate into the Applied Biosystems™ 7500 Fast Real-Time PCR System, and follow the thermal cycling protocol listed in “Cycling Conditions and Instrument Settings”.
7. When the run is complete, follow the steps in “Analysis Settings” to analyze the data. For the ABI 7500 Fast, use the average final normalized fluorescence of the diluted Positive Control amplification curves to set the Threshold for the FAM dye channel.
8. The following results must be obtained for the RUO instrument to be qualified for testing using the EZ-SARS-CoV-2 Real-Time RT-PCR.

<b>Control Name</b>	<b>Expected SARS-CoV-2 (FAM) Ct Values</b>	
	<b>ABI 7500 Fast</b>	<b>T-COR 8</b>
Positive Control (undiluted)	≤ 33	≤ 35
Diluted Positive Control	< 40	< 40

**Appendix B: Label for RUO Instruments**









Please print and affix this label on any of the following instruments that have been qualified. If the instrument includes labeling indicating “For Research Use Only”, cover with the below “For Emergency Use Authorization Only” labeling. Retain this labeling throughout the EUA use of the EZ-SARS-CoV-2 Real-Time RT-PCR test.

- ABI 7500 Fast Real-Time PCR System
- Tetracore, Inc. T-COR 8™ Real-Time PCR Thermocycler

**For Emergency Use Authorization Only**

This instrument is authorized for use with the Tetracore, Inc. EZ-SARS-CoV-2 Real-Time RT-PCR that has received Emergency Use Authorization

### Symbols

Symbol	Meaning	Symbol	Meaning
	Catalog Number		Lot Number
	Expiration Date		Manufacturer
	Temperature Limit		<i>In Vitro</i> Diagnostic Medical Device
	Consult Instructions for Use		Caution

### Revision History

Revision	Date	Description of Change
<b>00</b>	<b>18 October 2021</b>	Initial Release
<b>01</b>	<b>12 May 2023</b>	Added ISO symbols and temperature ranges; Updated inclusivity <i>in silico</i> analysis
<b>02</b>	<b>20 October 2023</b>	Changed specimen type from nasal swabs to mid-turbinate nasal swabs and updated Performance Characteristics accordingly; Changed the use of RNase P results from for informational purposes only to being included in test result interpretation; Updated description of and dilution instructions for Positive Control; Updated inclusivity and cross-reactivity <i>in silico</i> analysis; Added procedure to qualify RUO instruments; Added label for RUO instruments; Minor grammatical and formatting changes
<b>03</b>	<b>11 December 2023</b>	Added instructions to pipette-mix extracted sample or control and prepared Mastermix; Added instructions for proper closure of T-COR 8™ tubes; Updated Clinical Evaluation section of Performance Characteristics; Updated undiluted Positive Control expected FAM Ct value for the ABI 7500 Fast in Appendix A
<b>04</b>	<b>13 March 2024</b>	Updated Symbols section; Adopted FDA's minor revisions to the following sections: Intended Use, Warnings and Precautions, Limitations, Conditions of Authorization for the Laboratory, Performance Characteristics, and Appendix B: Label for RUO Instruments

### How to Obtain More Information



Tetracore, Inc.  
77 Upper Rock Circle  
Suite 600  
Rockville, MD 20850

Tel: 240.268.5400  
Fax: 240.268.1107  
Email: sales@tetracore.com  
www.tetracore.com

**Tetracore® is a registered trademark of Tetracore, Inc.**